NAII
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Natural Alternatives International, Inc. is a formulator, manufacturer, and marketer of nutritional supplements. The company provides private-label contract manufacturing services for vitamins, minerals, herbal supplements, and other health care products. It offers comprehensive services including scientific research, clinical studies, proprietary ingredients, customer-specific formulation, product testing, marketing support, packaging design, regulatory review, and international product registration assistance. The company owns a patent estate related to beta-alanine, commercialized through the direct sale of raw material and supply agreements under the CarnoSyn, SR CarnoSyn, CarnoSyn 4X, and TriBsyn trademarks. Natural Alternatives International serves customers in the sports nutrition, wellness, healthy aging, and medical food channels, with a significant portion of its business derived from clients operating in the direct sales marketing channel. The company manufactures on two continents, with facilities in California, USA, and Manno, Switzerland, and distributes products globally. Founded in 1980, the company reorganized as a Delaware corporation in 1989. Its wholly owned subsidiary, Natural Alternatives International Europe S.A., operates a manufacturing and warehousing facility in Switzerland.

Summarised from the company's own disclosures, fiscal year ended Sep 2026

Industry Packaged Foods Homepage nai-online.com
Sector Consumer Defensive IR page nai-online.com/our-company/investors
Tags
nutritional supplements, contract manufacturing, beta-alanine, sports nutrition, private label, custom formulation, quality assurance testing, direct sales, wellness, medical food, CarnoSyn, SR CarnoSyn, CarnoSyn 4X, TriBsyn, SustainedRx, Perfect Synergy, Natural Alternatives International Europe S.A.
Press page —

Metrics

Valuation  
Market cap $ 9.326M
Market cap (USD) $ 9.326M
P/E -0.39
PEG —
P/BV 0.20
P/S 0.07
P/OCF -2.52
P/FCF -1.41
Dividend yield —
Turnover / mcap —
Returns  
ROE -35.0%
ROI -29.1%
ROIC -19.8%
Profit margin -14.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 22.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 5
Quality score -58.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 142.515M 129.86M 113.796M 154.015M 170.966M 178.52M 118.876M 138.29M 132.437M 121.946M 114.201M 79.508M 73.942M 62.797M 72.822M 55.882M 73.919M 81.755M 97.128M 99.131M 91.492M 78.534M 55.962M 50.037M 42.158M 47.827M
Net profit -20.695M -13.575M -7.217M 2.522M 10.712M 10.768M -1.645M 6.541M 5.051M 7.235M 9.546M 3.346M 1.994M 1.57M 4.158M 5.086M -4.08M -371K -5.285M 2.67M 2.199M 3M 1.105M 3.879M -4.889M -4.472M
Free cash flow -12.617M 2.318M -4.514M -6.505M -14.622M 15.699M -850K 1.237M -2.248M 8.783M -1.156M 970K 2.668M 2.849M -529K 7.37M 357K 1.316M 12.329M -6.111M -5.188M -38K 2.318M 3.727M 3.424M -6.81M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 2.39 3.28 6.02 7.2 10.44 16.83 6.86 11.66 10.15 10 11.04 5.67 5.3 4.61 6.74 4.33 6.42 8.08 6.49 10 6.98 — — — — —
Price performance 12m -0.27 -0.46 -0.16 -0.31 -0.38 1.45 -0.41 0.15 0.02 -0.09 0.95 0.07 0.15 -0.32 0.56 -0.34 -0.21 0.24 -0.35 0.43 — — — — — —

Filed figures

Figure Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 8.41M 14.6M 16M 17M 17.9M 17.4M 7.02M 16.9M 14.6M 20.7M
↳ YoY growth -36.4% +73.9% +9.2% +6.5% +5.6% -2.9% -59.7% +140.5% -13.3% +41.0%
↳ 5y CAGR -0.8% +17.2% +18.5% +11.4% +6.3% +15.7% -13.6% +1.1% -2.9% +2.8%
Lease liabilities (USD) — — 20.9M 18.8M 16.5M 22M 19M 47.7M 48.2M 31.3M
Cash and deposits (USD) 27.8M 23.6M 25M 30.5M 32.1M 21.8M 13.6M 12M 12.3M 7.39M
Right-of-use assets (USD) — — 20.8M 18.4M 15.9M 21.7M 20.4M 43.5M 41.1M 24.1M
Cash flow detail
Operating cash flow (USD) 14.1M 1.83M 6.56M 3.69M 20.8M 11.9M 7.02M -1.5M 5.93M -8.92M
Purchases of property, plant and equipment (USD) -5.35M -4.08M -5.33M -4.54M -5.11M -26.5M -13.5M -3.02M -3.61M -3.7M
Change in receivables (cash effect) (USD) 4.81M -6.21M -1.34M -4.32M -813,000 644,000 11.8M -9.87M 2.25M -6.01M
Change in inventories (cash effect) (USD) 7.04M -9.84M -2.44M -1.97M 966,000 -5.47M 2.78M 5.45M -622,000 -5.88M
Change in payables (cash effect) (USD) -8.01M 4.44M -491,000 2.72M 1.91M 3.06M -8.61M 5.39M 2.86M 4.06M
Share buybacks (cash effect) (USD) -712,000 -510,000 -1.37M -3.75M -4.15M -5.5M -1.5M -221,000 -178,000 -89,000
Interest paid (cash effect) (USD) — -9,000 -23,000 -66,000 -131,000 -206,000 -802,000 -285,000 -814,000 -1.08M
Income taxes paid (cash effect) (USD) -2.89M -1.82M -1.97M -993,000 -2.96M -2.61M -1.84M -463,000 -323,000 -435,000
Share-based compensation (USD) 1.03M 1.33M 1.67M 1.71M 1.43M 968,000 1.02M 1.2M 977,000 603,000
Operating cash flow before change in receivables (USD) 9.33M 8.04M 7.91M 8.01M 21.6M 11.2M -4.8M 8.37M 3.69M -2.91M
Free cash flow (OCF - PPE - intangibles) (USD) 8.78M -2.25M 1.24M -850,000 15.7M -14.6M -6.51M -4.51M 2.32M -12.6M
Income detail
Research and development expense (USD) 1.6M 1.5M 1.8M 1.8M 1.9M 2.5M 2.1M 1.9M 1.8M 2.3M
↳ 5y CAGR +7.8% +4.6% +13.7% +10.4% +11.6% +9.3% +7.0% +1.1% 0% +3.9%
Total comprehensive income (USD) 7.01M 5.38M 7.41M -2.99M 11.4M 13M 740,000 -7.16M -15M -19M
Comprehensive income to owners (USD) 7.01M 5.38M 7.41M -2.99M 11.4M 13M 740,000 -7.16M -15M -19M
Provision for credit losses (USD) — — — 3.28M -132,000 -120,000 -1.42M 0.00 — —
Credit cost ratio (credit losses / average receivables) (%) — — — 19.9% 0.8% 0.7% 11.7% 0.0% — —
Reported Sep 18, 2017 Sep 19, 2018 Nov 14, 2019 Sep 21, 2020 Sep 20, 2021 Sep 21, 2022 Sep 21, 2023 Sep 27, 2024 Sep 23, 2025 Sep 28, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Collagen Supplement Manufacturer | NAI Bull 0 Bear 0 Other

NAI Logo

View eBook Request A Quote

What Does Contract Manufacturing a Collagen Supplement Actually Involve?

Collagen has become one of the most requested categories for brands entering the supplement space, but a collagen supplement manufacturer needs to handle some ingredient quirks that do not come up with most other formulas. Natural Alternatives International (NAI) works with brands building powder and capsule products that require this kind of formulation attention. Getting the correct sourcing, format, and processing decisions up front makes the difference between a collagen product that performs and one that falls flat with consumers.

Why Does Collagen Present Unique Formulation Challenges Compared to Other Powders and Capsules?

Collagen behaves differently than most powdered ingredients. It’s hygroscopic, meaning it readily absorbs moisture from the air, which can affect flow during production and shelf stability after packaging if humidity isn’t controlled carefully.

Particle size and solubility also matter more with collagen than with many other ingredients. A poorly processed collagen powder can clump or fail to dissolve cleanly, which shows up immediately to a consumer mixing it into a drink. Collagen contract manufacturing has to account for this at the blending stage, not as an afterthought during quality checks.

Taste and mouthfeel add another layer. Unflavored collagen has a distinct texture that some consumers notice more than they would with a typical vitamin powder, so formulation decisions around particle consistency directly affect how a finished product is received.

What Sourcing Questions Matter Most When Choosing a Collagen Ingredient Supplier?

Not all collagen sources are created equal, and the sourcing decision shapes everything from cost to label claims. Brands should be asking their manufacturing partner about:

  • Source type: bovine, marine, and chicken-derived collagen each carry different price points, amino acid profiles, and consumer perceptions
  • Hydrolyzation quality: properly hydrolyzed collagen peptides affect solubility and absorption, and inconsistent hydrolyzation can lead to a gritty or clumpy final product
  • Traceability documentation: brands making sustainability or origin claims need a supplier who can back those claims with real supply chain records
  • Heavy metal and contaminant testing: collagen sourced from animal byproducts requires rigorous testing protocols to meet safety standards

Why This Matters Beyond the Label

These sourcing questions aren’t just compliance checkboxes. A supplier who can’t answer them clearly is often a sign of a manufacturing partner without the in-house formulation science needed to catch problems before they reach a finished batch.

How Does Capsule Format Compare to Powder Format for a Collagen Product Line?

Powder is the more common format for collagen, largely because the effective dose tends to run higher than what a capsule can comfortably hold. A typical collagen serving often requires several grams, which would mean swallowing a large number of capsules to hit an equivalent dose.

Capsule format still has a place in a collagen product line, particularly for brands targeting convenience-focused consumers who don’t want to mix a powder into a drink. The tradeoff is dose size versus convenience, and brands sometimes offer both formats to serve different parts of their customer base.

Working with a manufacturer capable of both high-volume powder and capsule production gives a brand the flexibility to test one format first and expand into the other without switching partners mid-launch.

Ready to Build Your Collagen Line With NAI?

NAI brings formulation expertise to the sourcing, processing, and format decisions that make or break a collagen product. If you’re planning a collagen

Request a Quote

CAPABILITIES

▶ Manufacturing

▶ Packaging

▶ Quality Assurance Testing

▶ Stability Programs

▶ Custom Formulation

Global Contract Manufacturing Solutions Since 1980

Capabilities

Our Approach

Company

Contact Us

Job Opportunities

Investors

News

Request A Quote

© Copyright 1999-2025, Natural Alternatives International, Inc. Privacy Policy

Global Contract Manufacturing Solutions Since 1980

Capabilities

Our Approach

Company

Contact Us

Job Opportunities

Investors

News and Events

Request A Quote

Capsule Contract Manufacturing vs Tablet | NAI Bull 0 Bear 0 Routine

NAI Logo

View eBook Request A Quote

Capsule or Tablet: What Actually Decides the Right Format for Your Formula?

Choosing between a capsule and a tablet feels like a small decision until it starts shaping cost, timeline, and even how well certain ingredients hold up. Natural Alternatives International (NAI) works with brands weighing capsule contract manufacturing against tablet production every day, and the right answer usually comes down to the formula itself rather than personal preference. Understanding what drives that decision early can save a brand from a costly reformulation down the road.

Where Do Capsule and Tablet Manufacturing Processes Genuinely Diverge?

Capsules are filled, not compressed. A two-piece shell holds a powder, granule, or blend, and the manufacturing process centers on precise dosing into that shell rather than applying pressure to a formula.

Tablets go through a compression process instead. Powders are blended, often granulated, then pressed under high pressure into a solid form. This adds steps that capsule production doesn’t require, including binding agents to hold the compressed shape together and, in many cases, an additional coating stage.

These process differences carry real implications for custom tablet manufacturer selection . A partner running high-volume compression equipment needs different quality controls than one focused on capsule filling, since compression introduces variables like tablet hardness and disintegration time that capsules don’t face in the same way.

Which Ingredients Hold Up Better in a Capsule Versus a Compressed Tablet?

Some ingredients simply behave better in one format than the other. Capsules tend to work well for:

  • Oily or waxy ingredients that resist compression into a solid tablet
  • Odor-sensitive formulas, since capsule shells contain smell better than an exposed tablet surface
  • Heat-sensitive compounds that could degrade under the pressure and friction of compression
  • Larger single-dose formulas where the fill volume of a capsule offers more flexibility than a tablet’s compressed size limits

Tablets often perform better for:

  • Stable, dry powder blends that compress cleanly without binding issues
  • Formulas needing extended or delayed release, since tablet coatings can control how and when the compound is absorbed
  • Products requiring precise scoring for split dosing
  • High-volume, low-cost production runs where compression speed offers an efficiency advantage over capsule filling

A Quick Gut Check for Brands

If a formula includes oils, strong-smelling botanicals, or heat-sensitive actives, capsule contract manufacturing is usually the safer starting point. If the formula is a stable dry blend built for high-speed production, tablet compression tends to be the better fit.

What Cost and Timeline Differences Are Worth Knowing Before You Pick a Format?

Tablet production often costs less per unit at scale, since compression equipment can run faster once a formula is dialed in. That said, getting to that point can take longer, because tablet formulas frequently require additional development work around binders, disintegration time, and coating before a batch is production-ready.

Capsule production tends to move faster from formula to finished batch, since filling doesn’t require the same level of process tuning that compression does. This can matter for brands working against a launch deadline or testing a new formula before committing to a larger production run.

Working with a partner offering both high-volume capsule and tablet manufacturing under one roof gives a brand room to pilot a format decision without starting over with a new vendor if the first choice doesn’t hold up. Pairing that with custom supplement formulation support also means format and formula get worked out together instead of the format being locked in before the formula is fully tested.

Ready to Choose the Right Format With NAI?

NAI runs capsule and tablet production side by side, so brands get an honest recommendation instead of a one-size-fits-all answer. If you’re not sure which format fits your formula, NAI’s team can help you figure it out before you commit to a production run.

Request a Quote

CAPABILITIES

▶ Manufacturing

▶ Packaging

▶ Quality Assurance Testing

▶ Stability Programs

▶ Custom Formulation

Global Contract Manufacturing Solutions Since 1980

Capabilities

Our Approach

Company

Contact Us

Job Opportunities

Investors

News

Request A Quote

© Copyright 1999-2025, Natural Alternatives International, Inc. Privacy Policy

Global Contract Manufacturing Solutions Since 1980

Capabilities

Our Approach

Company

Contact Us

Job Opportunities

Investors

News and Events

Request A Quote

Turnkey Packaging for Supplements | NAI Bull 0 Bear 0 Other

NAI Logo

View eBook Request A Quote

What Does Turnkey Packaging Actually Include?

Brands searching for a smoother path from formula to store shelf often run into the term “turnkey packaging” without a clear sense of what it covers. Natural Alternatives International (NAI) works with brands who want one point of contact instead of juggling separate vendors for filling, labeling, and shipping prep. Understanding what a true turnkey packaging setup includes helps brands set the right expectations before signing a manufacturing agreement.

Turnkey Packaging vs Coordinating Several Vendors Yourself: What’s the Real Difference?

Coordinating packaging on your own usually means managing multiple vendors: one for bottles or blister packs, another for labels, and possibly a third for final assembly and shipping prep. Each handoff creates a new point where timelines can slip or quality can slide.

Turnkey packaging consolidates these steps under a single contract manufacturing and packaging partner. The brand supplies the formula and brand direction, and the manufacturer handles the rest, from container selection through the final sealed unit ready for distribution.

This matters most for smaller teams without a dedicated operations person to manage vendor relationships. A single point of accountability means fewer emails, fewer delays waiting on separate suppliers, and one team responsible for catching problems before a shipment goes out. Working with a manufacturer offering finished goods packaging as part of the core service removes most of that coordination burden entirely.

What’s Typically Included, and What’s Billed Separately, in a Turnkey Quote?

A turnkey packaging quote generally bundles more than brands expect, but it’s worth knowing where the line usually sits.

Typically included in a turnkey quote:

  • Container and format selection (bottles, blister packs, pouches, or stick packs)
  • Filling and sealing
  • Label application
  • Basic quality checks before shipment
  • Case packing for distribution

Often billed separately:

  • Custom label design work
  • Specialty packaging inserts or tamper-evident bands beyond standard options
  • Expedited shipping or rush production fees
  • Warehousing beyond a standard hold period

Why This Distinction Matters

Brands who assume everything is bundled sometimes get surprised by add-on costs later in the process. Asking a potential partner for an itemized breakdown before signing avoids that friction and makes budget planning far more accurate.

How Does Going Turnkey Shorten the Road From Formula to Shelf?

Every vendor handoff in a fragmented supply chain adds waiting time. A formula sitting at one facility while packaging materials are sourced elsewhere means delays stack on top of each other before a single unit reaches a shelf.

A turnkey setup removes most of that waiting. Because custom supplement formulation and packaging happen under one operation, production scheduling can move in parallel instead of in sequence. Materials can be lined up while the formula is being finalized rather than waiting for a separate vendor relationship to start from scratch.

This shows up most clearly for brands under a launch deadline, whether that’s a retail commitment, a seasonal window, or a funding milestone tied to a product being on shelves. A high-volume manufacturing partner running packaging in-house can typically compress a timeline that would otherwise stretch across several separate contracts.

Ready to Simplify Your Packaging With NAI?

NAI handles formulation, manufacturing, and packaging under one roof, so brands get a true turnkey experience instead of managing separate vendors. If your product is ready to move from formula to finished shelf-ready unit, NAI’s team can walk you through the process.

Request a Quote

CAPABILITIES

▶ Manufacturing

▶ Packaging

▶ Quality Assurance Testing

▶ Stability Programs

▶ Custom Formulation

Global Contract Manufacturing Solutions Since 1980

Capabilities

Our Approach

Company

Contact Us

Job Opportunities

Investors

News

Request A Quote

© Copyright 1999-2025, Natural Alternatives International, Inc. Privacy Policy

Global Contract Manufacturing Solutions Since 1980

Capabilities

Our Approach

Company

Contact Us

Job Opportunities

Investors

News and Events

Request A Quote

Prompts

Natural Alternatives International, Inc. (ticker NAII), listed in United States.

ETFs Holding Natural Alternatives International, Inc.

ETF Weight in ETF Shares Market value As of
DFSV 0.00% 141,533 $ 134.527K Nov 12, 2026
DXUV 0.00% 8,015 $ 7,618.26 Nov 12, 2026
DFAS 0.00% 42,450 $ 40.349K Nov 12, 2026
DCOR 0.00% 10,277 $ 9,768.29 Nov 12, 2026
DFAC 0.00% 16,603 $ 15.781K Nov 12, 2026
BSVO 0.00% 24,906 $ 20K Nov 18, 2026